A meta-analysis showed that TLR9 polymorphisms are associated with increased risk for cancer and some hematological neoplasms, such as non-Hodgkin’s lymphoma and acute myeloid leukemia (AML)37–39. Here, TLR9 is linked to non-Hodgkin lymphoma.